The Potential of Soluble Epoxide Hydrolase Inhibition in the Treatment of Cardiac Hypertrophy
~:'~: mall molecule inhibitors of soluble .~). 'epoxide hydrolase (sEH) have been shown to reduce blood pressure, inflammation, and pain in a number of mammalian disease models. In fact, an inhibitor of sEH has been moved into clinical trials for the treatment of hypertension. The beneficial effect of sEH inhibition is thought to be due to the role of sEH in the metabolism of anti-inflammatory, antihypertensive, and analgesic lipid signaling molecules such as the epoxyeicosatrienoic acids. Recently, application of sEH inhibitors in animal models of cardiac hypertro phy have produced promising results.
In this review, we describe these results and discuss the effect of sEH inhibitors on the inflammatory NF-lCB pathway and the implication this has for the treatment of cardiac hypertrophy. Inhibitors sEH are in clinical tri als as oral drugs for the treatment of hypertension. Based on animal mod els, sEHI appears to reduce the vascu lar inflammation and end-organ dam age that commonly are associated with hypertension. There appears to be a dramatic reduction in renal damage in angiotensin and deoxycorticosterone acetate-salt models of hypertension. Moreover, sEH inhibitors have been shown to have an anti-inflammatory action' and may be particularly useful in hypertensive patients, in whom it is important to control blood pressure in the presence of a systematic inflam matory disease. Animal models indi cate that sEH inhibitors, presumably working through epoxylipid chemical mediators, reduce the progression of atherosclerotic plaque as well as infarct size associated with ischemic heart injury.2 An unexpected finding, how ever, was the dramatic reduction in cardiac hypertrophy in several model systems,) which will be the focus of the present article. In addition, we will summarize recent literature on sEH and sEH inhibitors.
iEndothe~ium-Derived

Hyperpolarizing Factors
By inhibiting sEH, the levels of endog enous chemical mediators, includ ing the epoxides of arachidonic acid (AA), epoxyeicosatrienoic acids (EETs),' and other epoxylipids, are increased and the corresponding diol products of the enzyme are decreased (Figure 1 ). These epoxide-containing lipids are thought to be major con tributors to the endothelium-derived hyperpolarizing factors (EDHFs) that lead to relaxation of vascular smooth muscle. I Over the last few years, it has become clear that regulation of the EDHFs is intimately tied to the renin-angiotensin-aldosterone system (RAAS) for blood pressure regulation. The EDHF complex is a sufficiently important contributor to vascular biol ogy and hypertension, and we often refer to the EDHF RAAS.
There is growing evidence that the EDHF system is affected in cardiovas cular disease states, such as hyperten sion, diabetes, chronic renal failure, and aging. Moreover, recent stud ies have suggested the link between EDHFs and the RAAS. For example, chronic treatment with RAAS inhibi tors improves the age-related impair ment of EDHF-mediated responses. 4 Indeed, several clinical studies have shown that blocking the RAAS can improve endothelial function not only in hypertensive patients but also in normotensive patients with cardiovas cular disease. s
Although the exploitation of a new mechanism for the treatment of hyper tension is the major driver for mov ing sEH inhibitors into clinical trials, the compounds influence physiology in a number of ways. For example, The structure of a/~-hydrolases consists of ~ sheets and a helices con nected by [oops that position catalytic residues, The "catalytic triad" contains a catalytiC nucleophile (aspartate, cysteine, or serine) and an acid-base pair that activates a molecule of water,9 The sEH catalytic triad contains an aspartate nucleophile and an aspartate histidine acid-base pair. 9 In addition to this triad, two tyrosines have been implicated in polarizing the epoxide moiety, making the substrate more sus ceptible to nucleophilic attack,9
Epoxides are 3-member cyclic ethers, Compounds that contain epox ide moieties can be highly reactive and mutagenic, as is the case with arene oxides, but they can also be physiologically stable, as are most lipid epoxides,IO Epoxides such as cyclo diene epoxides can even be environ mentally stable, 10 Classes of lipid epox ides have been implicated as paracrine and autocrine signaling molecules in mammals, Two examples of epoxide containing lipid signals are the EETs and the leukotoxins (EpOMEs), These are epoxides of AA (20:4) and linoleic acid (18:2), respectively, formed large ly but not exclusively by cytochrome P450s (CYP) ,B,II These lipid signaling molecules have been shown to playa role in regulation of inflammation and hypertension in various mammalian systems,6,7 Other metabolites of AA include the prostanoids, formed by cyclooxygenases, and the leukotrienes and prostaglandins, formed by lipox ygenases,12 Both of these branches of the AA cascade have been tar geted by pharmaceutical companies for the treatment of inflammatory pain (eg, celecoxib) and asthma (eg, montelukast) , sEH converts the lipid signaling molecules, such as the EETs, to their corresponding diols, In the case of the EETs, the diols are called elihy droxyeicosatrienoic acids (DHETs),B The DHETs may still possess some vasodilatory effect,8 but overall, the transformation of EETs to DHETs by sEH should reduce biologic activity, increase the excretion of the com pound, and inhibit their incorpora tion into lipid membranes,s thereby attenuating the vasodilatory or anti inflammatory signal in those tissues, In addition to its action on the EETs, sEH metabolizes the EpOMEs to a more toxic diol species,b These diols have been implicated in the onset of acute respiratory distress syndrome (ARDS), an inflammatory disease that causes sudden pulmonary failureY They may also be endogenous chemi cal mediators responsible, for example, for increasing vascular permeability,~ sEH also metabolizes the epoxides of the omega-3 fatty acids docosa hexaenoic and eicosapentaenoic acid, which have been shown to be formed by CYPs and have anti-inflammatory effects in vitro, 13, 14 One example of the balance of lipid signals and the effect of sEH epoxide hydrolase activity occurs in the renal vasculature, where the CYP metabo lite of AA 20-HETE has been shown to have a vasoconstrictive effect, while 14,15-and 11, 12-EETs have a vasodi latory effect, IS Hypothetically, if the EETs are hydrolyzed to their corre sponding diols by sEH and then excret ed, there will be a relative increase of the vasoconstrictive signal over the vasodilatory signal, which should result in an increase in blood pressure. The situation is complicated by the fact that 8,9-EET has been shown to
~'P',tlight 011 heart fnilure trCIl1slClliol1(J1 reseorch Earlier compounds such as AUDA (12-(3-adamantan-l-yl-ureido) -dode canoic acid) were highly lipophilic and difficult to deliver as well as being met abolically unstable. AEPU (l-adaman tan-3-(5-(2-(2-ethylethoxy)ethoxy) pentyl) urea) represents a compound that is more water-soluble and pen etrates membranes well. Newer com pounds such as t-AUCB and TPAU have better oral bioavailability and metabolic stability than their prede cessors, possibly associated with great er water solubility. Some, like AUDA and t-AUCB, are very potent on the sEHs of many species. However, others such as TPAU can vary greatly in their potency. For example, TPAU has poor inhibitory activity on canine and feline sEHs (Figure 2 ). Early inhibitors of sEH such as DCU and AUDA employed a potent central urea pharmacophore, but they had low solubility. This pharmacophore was retained while the solubility was improved by adding more polar groups such as the polyethylene glycol tail in AEPU. These more soluble compounds are suitable for infusion, nebulization, or oral administration, whereas less soluble compounds such as t-TUCB are used for subcutaneous injection or slow-release formulations. Several compounds have been developed with ICsos in the low-nanomolar/high-picomolar range that remain in circulation for over a day, as is the case with tAUCB, or are metabolized in a matter of hours, as occurs with AEPU. The low blood level of AEPU does not reflect intercellular concentration because the compound easily penetrates plasma membranes. In fact, AEPU dis played high efficacy in several mammalian disease models. The incorporation of fluorides produces molecules such as TUCF, TPAU, and t-TUCB, which can be used to impregnate stents for slow release of the compound at sites that are suscep tible to inflammation. IC so assays were determined with the fluorescent substrate (3-phenyl-oxiranyl) -acetic acid cyano-(6-methoxy-naphthalen-2-yl) -methyl ester with purified recombinant human sEH. cLogP values are calculated estimates of the octanol/water partition coefficients commonly utilized in predicting a molecule's properties. Algorithms for cLogPs are often poor indicators of 10gP for ureas, but they give a good indication of relative lipophilicity. These values were calculated with the ChemOffice suite (CambridgeSoft Corporation, Cambridge, MA).
sEH Inhibitors and Cardiac Hypertrophy and Failure
Cardiac hypertrophy is the heart's compensatory response to a variety of extrinsic and intrinsic stimuli includ ing pressure or volume overload, mutations of sarcomeric proteins, or loss of contractile mass from previ ous myocardial infarction. Cardiac hypertrophy is believed to have a compensatory function by diminishing wall stress. Yet, paradoxically, ven tricular hypertrophy is associated with a significant increase in the risk of heart failure and malignant arrhyth mia. To disentangle physiologic from pathologic hypertrophic growth, the molecular mechanisms that initiate the compensatory growth response or that precipitate the transition to heart failure have undergone intense investigations, and there is increas ing evidence from antihypertensive agents that cardiac hypertrophy may represent a new therapeutic target to improve survival in patients. 16 Motivated by the therapeu tic potential, we recently tested the effects of sEH inhibitors on the development and reversal of cardiac hypertrophy using a murine model of thoracic aortic constriction. We showed that there is an almost com plete resolution of cardiac hypertrophy by sEH inhibitors independent of the antihypertensive effects (Figure 3) . 
AEPU
The beneficial effects of sEH inhibi tors were assessed using noninvasive cardiac echocardiography as well as histologic examination, as shown in Figure 3 . Moreover, our study shows a beneficial effect of sEH inhibitors in the prevention of cardiac arrhythmias that occur in association with cardiac hypertrophy. In addition to the pre vi()usly described anti-inflammatory and antihypertensive effects of sEH inhibitors, the increase in the em10g enous levels of EETs by inhibiting the 19 EETs inhibit IKK, prevent ing degradation of IKB and main taining NF-KB in its inactive form. 1 11, 12-EET has been shown to produce the most potent effect in endothe lial cells by inhibiting IKK-mediated phosphorylation of IKBa. I Because sEH converts EETs to DHETs, inhibi tion of sEH may represent a potential approach for enhancing the biolog ic activity of EETs.I,9 On the other hand, the potential beneficial effects of sEH inhibitors in cardiac hypertro phy remain unexplored to date.
Using both in vivo and in vitro mod els of cardiac hypertrophy, our data sug gest an inhibitory effect of sEH inhibi tors on the NF-KB pathway (Figure 4) , The NF-KB pathway has been implicat ed as a pivotal intracellular mediator of the inflammatory response associated with a variety of disease processes as well as cell growth and apoptosis,l8 Recently, several studies have implicated NF-KB activation as a causal event in cardiac hypertrophic response, as modeled in cultured cardiac myocytes as well as in vivo model. 10 Purcell and Molkentin 20 demonstrated that viral mediated transfer of a "superrepressor" I KBa protein, a dominant negative NF-KB approach, prevented cardiomyocyte hypertrophy in response to G-protein coupled receptor (GPCR) agonists such as phenylephrine, endothelin-l, and angiotensin II. A crucial role for NF-KB activation in myotrophin induced and GPCR-related cardiac hypertrophy in vivo has been dem onstrated.21.22 Taken together, evi dence now exists to support the notion that NF-KB plays a necessary role for myocyte hypertrophy in vitro and in vivo, at least downstream of GPCR agonist stimulation.
NF-KB signaling in the heart is extremely complex. Several signal ing pathways implicated in cardiac hypertrophy and failure are capa ble of activating NF-KB including a-adrenergic stimulation, angio tensin II, PI3K/Akt, p38, ras, 26 MEKKl/4, PKC, and gp130.
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Signaling by gp130 activates NF-KB via ras, ]ak/Stat, and/or PI3K/Akt signaling and is required for pressure overload-induced cardiac hypertro phy.27 Several components of sig naling cascades implicated in car diac hypertrophy are also involved in cytokine-activated pathways that culminate in NF-KB activa tion. Conversely, cytokine-activat ed pathways activate many of the MAPK signaling cascades implicated in cardiac hypertrophy. 28 The linkage between NF-KB and myocyte hypertrophy is especially intriguing given the long-standing hypothesis that inflammatory cytok ines, for example, tumor necrosis fac tor (tumor necrosis factor a [TNFa] and interleukin-l [Ill]) are relevant mediators of cardiomyopathic dis ease states and that NF-KB itself is dominantly regulated by the cytokine TNFa. 29 Heart failure patients typi cally have elevated levels of circulat ing TNF-a in the blood and have significant myocardial NF-KB activa tion. 29 NF-KB has been shown to be involved in the direct regulation of both proapoptotic and antiapoptotic genes, including antiapoptotic factors such as clAPs, Bcl-2 family (Bcl xL), and FLICE inhibitory protein, as well as proapoptotic factors such as Fas, FasL, caspase-8, caspase-ll, and TNFa. 30 This is especially relevant given the hypothesis that cardiac myocyte apoptosis can exacerbate or even initiate heart failure. Taken together, the beneficial effects of blocking NF-KB by sEH inhibition in cardiac hypertrophy remain to be systematically investigated. Further experiments are needed to define the molecular mechanisms responsible for the observed inhibitory effects of sEH inhibitors on the development of cardiac hypertrophy. Finally, addi tional information is urgently needed to establish whether the observed beneficial effects are generalizable to other animal models of hypertrophy and especially to patients with car diac hypertrophy and failure. There is consequently an enormous and excit ing opportunity to uncover a poten tially very powerful group of com pounds that may be used effectively in the clinical setting and at the very least will deepen our understanding of the AA cascade and the develop ment of cardiac hypertrophy. 
